Derrick Miyao - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Derrick Miyao's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Derrick Miyao
Verified
Vice President Molecular Foundry, deepcure.ai
San Diego
Beats
Transportation , History, Technology , Northern California, Politics, Urban Development
Content
By Derrick Miyao| deteched.com@ I thought SPAM to my email inbox was annoying, until unknown spam callers started to blow up my phone every single day. I continue to get calls no matter what tools I have used to block annoying people: FCC do not call list, Robocaller subscription, or AT&T’s spam blocker to name a few. The calls are not only disruptive, but there’s a high chance that many of them are looking to steal from you in one way or another. It’s simply a pain in the butt.
By Derrick Miyao| deteched.com@ Samsung is stepping up to do its part to take care of those who take care of us. In this unprecedented time of a global pandemic, Samsung has setup a brand new program to repair its smartphones for doctors, nurses, EMTs, medical staff, hospital staff, nursing home staff, pharmacists, law enforcement and firefighters, including volunteer firefighters. I commend Samsung for keeping our hero’s devices working at optimal performance so they have one less worry on their plate.
By Derrick Miyao| deteched.com@ I thought SPAM to my email inbox was annoying, until unknown spam callers started to blow up my phone every single day. I continue to get calls no matter what tools I have used to block annoying people: FCC do not call list, Robocaller subscription, or AT&T’s spam blocker to name a few. The calls are not only disruptive, but there’s a high chance that many of them are looking to steal from you in one way or another. It’s simply a pain in the butt.
Company Info
deepcure.ai
DeepCure is a biotechnology company founded in 2018 by researchers from the MIT Media Lab, based in Boston. The company focuses on small-molecule drug discovery, utilizing Artificial Intelligence (AI) to enhance pharmaceutical development. DeepCure aims to deliver better drugs more quickly and affordably by addressing challenging drug targets that traditional methods struggle to tackle. The company's core service is its AI platform, which accurately searches through a vast chemical space. This platform employs deep learning algorithms and a proprietary database of over one trillion chemistries to identify novel drug candidates. DeepCure also innovates in chemical synthesis with its Inspired Chemistry platform, capable of automating complex workflows, including the production of nirmatrelvir, the active ingredient in Paxlovid. One of DeepCure's notable drug candidates is DC-9476, a selective Brd4 BD2 inhibitor showing promise in preclinical models for autoimmune diseases like rheumatoid arthritis. The company collaborates with institutions such as the Leeds Institute of Rheumatic and Musculoskeletal Medicine to further test this candidate and is actively seeking partnerships for new small molecule discovery projects.
Founded: 2018